• Je něco špatně v tomto záznamu ?

Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds

U. Özgen, SÖ. Şener, K. Šmejkal, J. Vaclavik, FS. Şenol Denİz, İ. ErdoĞan Orhan, E. Svajdlenka, A. C GÖren, M. ŽemliČka,

. 2020 ; 17 (5) : 528-534. [pub] 20201030

Jazyk angličtina Země Turecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21002035

Objectives: The scope of the present study was to specify the therapeutic potential for neurodegenerative diseases through evaluating cholinesterase and tyrosinase (TYR) inhibitory and antioxidant activity of Lysimachia verticillaris (LV), and to isolate the major compounds considering the most active fraction. Materials and Methods: The methanol extract (ME) of LV and the chloroform, ethyl acetate (EtOAC), and aqueous fractions obtained from it were used for biological activity and isolation studies. The ME and all fractions were tested for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and TYR inhibitory and antioxidant potentials using ELISA microtiter assays. Seven major compounds were isolated from the active EtOAC fraction by semi-preparative high performance liquid chromatography. The structures of the compounds were elucidated by several spectroscopic methods. Results: Marked AChE inhibitory activity was observed in the EtOAC fraction (6337±1.74%), BChE inhibitory activity in the ME and EtOAC fraction (85.84±3.01% and 83.82±3.93%), total phenol content in the EtOAC fraction (261.59±3.95 mg equivalent of gallic acid/1 g of extract) and total flavonoid contents in the EtOAC fraction (515.54±2.80 mg equivalent of quercetin/1 g of extract), and 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity and ferric-reducing antioxidant power values in the aqueous and EtOAC fractions (92.54±0.67%, 92.11±0.30%; 2.318±0.054, 2.224±0.091, respectively). Accordingly, the isolation studies were carried out on the EtOAC fractions. Compounds 1-7 (gallic acid, (+)-catechin, myricetin 3-O-arabinofuranoside, myricetin 3-O-α-rhamnopyranoside, quercetin 3-O-β-glucopyranoside, quercetin 3-O-arabinofuranoside, and quercetin 3-O-α-rhamnopyranoside, respectively) were isolated from the active EtOAC fraction. Conclusion: LV may be a potential herbal source for treatment of neurodegenerative diseases based on its strong antioxidant activity and significant cholinesterase inhibition similar to that of the reference.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21002035
003      
CZ-PrNML
005      
20210126092831.0
007      
ta
008      
210105s2020 tu f 000 0|eng||
009      
AR
024    7_
$a 10.4274/tjps.galenos.2019.71598 $2 doi
035    __
$a (PubMed)33177934
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a tu
100    1_
$a Özgen, Ufuk $u Karadeniz Technical University Faculty of Pharmacy, Department of Pharmacognosy, Trabzon, Turkey.
245    10
$a Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of Lysimachia verticillaris L. and Isolation of the Major Compounds. / $c U. Özgen, SÖ. Şener, K. Šmejkal, J. Vaclavik, FS. Şenol Denİz, İ. ErdoĞan Orhan, E. Svajdlenka, A. C GÖren, M. ŽemliČka,
520    9_
$a Objectives: The scope of the present study was to specify the therapeutic potential for neurodegenerative diseases through evaluating cholinesterase and tyrosinase (TYR) inhibitory and antioxidant activity of Lysimachia verticillaris (LV), and to isolate the major compounds considering the most active fraction. Materials and Methods: The methanol extract (ME) of LV and the chloroform, ethyl acetate (EtOAC), and aqueous fractions obtained from it were used for biological activity and isolation studies. The ME and all fractions were tested for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and TYR inhibitory and antioxidant potentials using ELISA microtiter assays. Seven major compounds were isolated from the active EtOAC fraction by semi-preparative high performance liquid chromatography. The structures of the compounds were elucidated by several spectroscopic methods. Results: Marked AChE inhibitory activity was observed in the EtOAC fraction (6337±1.74%), BChE inhibitory activity in the ME and EtOAC fraction (85.84±3.01% and 83.82±3.93%), total phenol content in the EtOAC fraction (261.59±3.95 mg equivalent of gallic acid/1 g of extract) and total flavonoid contents in the EtOAC fraction (515.54±2.80 mg equivalent of quercetin/1 g of extract), and 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity and ferric-reducing antioxidant power values in the aqueous and EtOAC fractions (92.54±0.67%, 92.11±0.30%; 2.318±0.054, 2.224±0.091, respectively). Accordingly, the isolation studies were carried out on the EtOAC fractions. Compounds 1-7 (gallic acid, (+)-catechin, myricetin 3-O-arabinofuranoside, myricetin 3-O-α-rhamnopyranoside, quercetin 3-O-β-glucopyranoside, quercetin 3-O-arabinofuranoside, and quercetin 3-O-α-rhamnopyranoside, respectively) were isolated from the active EtOAC fraction. Conclusion: LV may be a potential herbal source for treatment of neurodegenerative diseases based on its strong antioxidant activity and significant cholinesterase inhibition similar to that of the reference.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Şener, Sıla Özlem $u Karadeniz Technical University Faculty of Pharmacy, Department of Pharmacognosy, Trabzon, Turkey.
700    1_
$a Šmejkal, Karel $u University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Natural Drugs, Brno, Czechia.
700    1_
$a Vaclavik, Jiri $u University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Natural Drugs, Brno, Czechia.
700    1_
$a Şenol Denİz, Fatma Sezer $u Gazi University Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Turkey.
700    1_
$a ErdoĞan Orhan, İlkay $u Gazi University Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Turkey.
700    1_
$a Svajdlenka, Emil $u University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Natural Drugs, Brno, Czechia.
700    1_
$a C GÖren, Ahmet $u Bezmialem Vakıf University Faculty of Pharmacy, Department of Chemistry, İstanbul, Turkey.
700    1_
$a ŽemliČka, Milan $u University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Natural Drugs, Brno, Czechia.
773    0_
$w MED00205978 $t Turkish journal of pharmaceutical sciences $x 2148-6247 $g Roč. 17, č. 5 (2020), s. 528-534
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33177934 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092827 $b ABA008
999    __
$a ind $b bmc $g 1614120 $s 1122319
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 17 $c 5 $d 528-534 $e 20201030 $i 2148-6247 $m Turkish journal of pharmaceutical sciences $n Turk J Pharm Sci $x MED00205978
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace